| Name | Title | Contact Details |
|---|
A vetted, virtual social club to play, date and evolve your love life. Launching 2021.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
PaxeraMed Corp. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With a track record of transformative leadership in healthcare technology, Figueroa will spearhead our efforts to integrate cutting-edge technology, streamline operations, and enhance patient care across our extensive network of community-based clinics.As a dynamic leader, Figueroa brings a wealth of experience in leveraging technology to optimize healthcare delivery. His strategic vision aligns perfectly with our commitment to providing the best possible care to our patients. He will play a pivotal role in advancing our digital infrastructure, fostering innovation, and ultimately, improving outcomes for those we serve.
Mulberry Grove is a Statham, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.